Toshiba Medical announced on Friday that its Aplio i900 premium cardiovascular ultrasound received FDA clearance. It was on display at the American College of Cardiology annual meeting in Washington, D.C. over the weekend.

“The Aplio i900 presents a real breakthrough in expanding the clinical utility of ultrasound, offering cardiologists a new tool for fast, safe and confident diagnoses even in technically difficult patient exams,” Dan Skyba, director of Toshiba's ultrasound business unit, said in a statement.

This ultrasound system is ideal for contrast, fetal, pediatric, stress echo and transesophageal echocardiography imaging.
The Aplio i900 is equipped with new features that enable clinicians to quickly examine patients with myocardial function, and quantify complex valvular lesions with greater depth and detail.

It can generate extreme processing power, which creates thinner beam slices and provides more information in each image. Its new beam-forming technology, called iBeam, offers better penetration, spatial resolution and contrast resolution.

Aplio i900 also has touch control screens and iSense technology to help improve productivity, as well as a real-time quick scan feature that makes automatic image adjustments.

This is the latest addition to Toshiba's premium Aplio i-series ultrasound platform, which was first introduced at the Radiological Society of North America annual meeting in 2014.

Cardiology Homepage